116 related articles for article (PubMed ID: 14613953)
1. Prenylation inhibitors: a novel class of antiviral agents.
Einav S; Glenn JS
J Antimicrob Chemother; 2003 Dec; 52(6):883-6. PubMed ID: 14613953
[TBL] [Abstract][Full Text] [Related]
2. Therapy for HDV!
Taylor JM
Hepatology; 2003 Dec; 38(6):1581-2. PubMed ID: 14655679
[No Abstract] [Full Text] [Related]
3. Prenylation of HDAg and antiviral drug development.
Glenn JS
Curr Top Microbiol Immunol; 2006; 307():133-49. PubMed ID: 16903224
[TBL] [Abstract][Full Text] [Related]
4. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus.
Bordier BB; Ohkanda J; Liu P; Lee SY; Salazar FH; Marion PL; Ohashi K; Meuse L; Kay MA; Casey JL; Sebti SM; Hamilton AD; Glenn JS
J Clin Invest; 2003 Aug; 112(3):407-14. PubMed ID: 12897208
[TBL] [Abstract][Full Text] [Related]
5. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles.
Bordier BB; Marion PL; Ohashi K; Kay MA; Greenberg HB; Casey JL; Glenn JS
J Virol; 2002 Oct; 76(20):10465-72. PubMed ID: 12239323
[TBL] [Abstract][Full Text] [Related]
6. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
7. Use of a prenylation inhibitor as a novel antiviral agent.
Glenn JS; Marsters JC; Greenberg HB
J Virol; 1998 Nov; 72(11):9303-6. PubMed ID: 9765479
[TBL] [Abstract][Full Text] [Related]
8. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
9. Novel targets of anti-hepatitis delta virus therapy.
Glenn JS; White JM
Prog Clin Biol Res; 1993; 382():53-60. PubMed ID: 8502717
[No Abstract] [Full Text] [Related]
10. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
11. Glucosidase inhibitors as antiviral agents for hepatitis B and C.
Durantel D; Alotte C; Zoulim F
Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228
[TBL] [Abstract][Full Text] [Related]
12. An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly.
Stray SJ; Johnson JM; Kopek BG; Zlotnick A
Nat Biotechnol; 2006 Mar; 24(3):358-62. PubMed ID: 16474383
[TBL] [Abstract][Full Text] [Related]
13. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
14. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy.
Konstantinopoulos PA; Papavassiliou AG
Trends Pharmacol Sci; 2007 Jan; 28(1):6-13. PubMed ID: 17150261
[TBL] [Abstract][Full Text] [Related]
15. Identification of selective inhibitors of VHSV from biased combinatorial libraries of N,N'-disubstituted 2,5-piperazinediones.
Mas V; Falco A; Brocal I; Perez L; Coll JM; Estepa A
Antiviral Res; 2006 Nov; 72(2):107-15. PubMed ID: 16730078
[TBL] [Abstract][Full Text] [Related]
16. Emerging host cell targets for hepatitis C therapy.
He Y; Duan W; Tan SL
Drug Discov Today; 2007 Mar; 12(5-6):209-17. PubMed ID: 17331885
[TBL] [Abstract][Full Text] [Related]
17. [Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment].
Wawrzynowicz-Syczewska M
Przegl Epidemiol; 2002; 56 Suppl 5():35-40. PubMed ID: 15553070
[TBL] [Abstract][Full Text] [Related]
18. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus.
Uckun FM; Pendergrass S; Qazi S; Samuel P; Venkatachalam TK
Eur J Med Chem; 2004 Mar; 39(3):225-34. PubMed ID: 15051170
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a hepatitis B and hepatitis delta virus receptor binding site.
Engelke M; Mills K; Seitz S; Simon P; Gripon P; Schnölzer M; Urban S
Hepatology; 2006 Apr; 43(4):750-60. PubMed ID: 16557545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
